Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Tekpli

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Genome Medicine|April 30, 2021
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancerMiriam Ragle Aure, Thomas Fleischer, Sunniva Bjørklund, et al.
Communications Medicine|June 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosisAndreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde, et al.
Oncoimmunology|January 14, 2026
Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypesLilly Anne Torland, Jürgen Geisler, Youness Azimzade, et al.
Cancer Research|August 19, 2007
Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cellsAmélie Rebillard, Xavier Tekpli, Olivier Meurette, et al.
Communications Biology|August 18, 2022
Subtype and cell type specific expression of lncRNAs provide insight into breast cancerSunniva Stordal Bjørklund, Miriam Ragle Aure, Jari Häkkinen, et al.
Nucleic Acids Research|September 26, 2022
A regulatory network comprising let-7 miRNA and SMUG1 is associated with good prognosis in ER+ breast tumoursLisa Lirussi, Dilara Ayyildiz, Yan Liu, et al.
Heliyon|July 23, 2024
Deep learning for automated scoring of immunohistochemically stained tumour tissue sections - Validation across tumour types based on patient outcomesWanja Kildal, Karolina Cyll, Joakim Kalsnes, et al.
Oncoimmunology|November 1, 2018
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumabShakila Jabeen, Manuela Zucknick, Marianne Nome, et al.
Oncoimmunology|February 5, 2019
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristicsShakila Jabeen, Jaime A Espinoza, Lilly Anne Torland, et al.
International Journal of Cancer|June 4, 2020
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancerHedda von der Lippe Gythfeldt, Tonje Lien, Xavier Tekpli, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Genome Medicine|April 30, 2021
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancerMiriam Ragle Aure, Thomas Fleischer, Sunniva Bjørklund, et al.
Communications Medicine|June 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosisAndreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde, et al.
Oncoimmunology|January 14, 2026
Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypesLilly Anne Torland, Jürgen Geisler, Youness Azimzade, et al.
Cancer Research|August 19, 2007
Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cellsAmélie Rebillard, Xavier Tekpli, Olivier Meurette, et al.
Communications Biology|August 18, 2022
Subtype and cell type specific expression of lncRNAs provide insight into breast cancerSunniva Stordal Bjørklund, Miriam Ragle Aure, Jari Häkkinen, et al.
Nucleic Acids Research|September 26, 2022
A regulatory network comprising let-7 miRNA and SMUG1 is associated with good prognosis in ER+ breast tumoursLisa Lirussi, Dilara Ayyildiz, Yan Liu, et al.
Heliyon|July 23, 2024
Deep learning for automated scoring of immunohistochemically stained tumour tissue sections - Validation across tumour types based on patient outcomesWanja Kildal, Karolina Cyll, Joakim Kalsnes, et al.
Oncoimmunology|November 1, 2018
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumabShakila Jabeen, Manuela Zucknick, Marianne Nome, et al.
Oncoimmunology|February 5, 2019
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristicsShakila Jabeen, Jaime A Espinoza, Lilly Anne Torland, et al.
International Journal of Cancer|June 4, 2020
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancerHedda von der Lippe Gythfeldt, Tonje Lien, Xavier Tekpli, et al.
Pageof 6